Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson's disease

Abstract

Early diagnosis and treatment of Parkinson's disease achieved through innovative nanoformulation strategies can improve safety as well as the efficacy of diagnostic and therapeutic agents. © 2019 Elsevier LtdParkinson's disease (PD) is the most common neurodegenerative disease and is associated with a loss of dopaminergic neurons in the substantia nigra. Currently available treatments provide only symptomatic relief and there is no proper diagnosis tool to detect early stages of PD. Recently, nanomedicines and nanoformulation strategies have been widely adopted for the diagnosis and treatment of PD owing to their ability to improve treatment efficacy and provide unique diagnostic functions. Furthermore, advances in nanomedicine limit the potential side effects associated with conventional therapy and provide targeted drug delivery. The objective of this review is to discuss nanoformulation strategies used for the treatment as well as the diagnosis of PD. © 2019 Elsevier Ltd